Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist.

Punit UpadhyayaJohanna LahdenrantaKristen HurovSailaja BattulaRachel DodsEric HainesMarianna KleymanJulia KristenssonJessica KublinRachid LaniJun MaGemma MuddElizabeth RepashKaterine Van RietschotenTom StephenFanglei YouHelen HarrisonLiuhong ChenKevin McDonnellPhilip BrandishNicholas Keen

Published in: Journal for immunotherapy of cancer (2021)

Tumor target-dependent CD137 agonism using a novel chemical approach (TICAs) afforded elimination of tumors with only intermittent dosing suggesting potential for a wide therapeutic index in humans. This work unlocks a new path to effective cancer immunotherapy via agonism of TNF superfamily receptors.

Keyphrases

rheumatoid arthritis
nk cells
high intensity
climate change
human health
transcription factor